Health Trials

Clinical trials

3

Search and review clinical trials. Use filters to narrow results by trial status, phase, treatment, biological sex and sponsor.

Condition / disease
Location
Status: Recruiting

A Phase Ib/II Study of ATG-022 Plus Pembrolizumab With/Without Chemotherapy in Participants With Claudin (CLDN) 18.2-positive, HER2-negative, Unresectable or Metastatic Gastric or Gastroesophageal Junction AdenocarcinomaUnresectable or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma

This is A Phase Ib/II Study of ATG-022 Plus Pembrolizumab With/Without Chemotherapy in Participants With Claudin (CLDN) 18.2-positive, HER2-negative, Unresectable or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma

Participants needed: 132
Trial details
Phase: Phase 1, Phase 2Age: 18+Biological sex: AllType: InterventionalSponsor: Antengene Biologics LimitedUpdated: Apr 14, 2026Locations: 30
Eligibility criteria

Provision of signed and dated, written informed consent prior to any study-speci... [+5]

Known active central nervous system metastases and/or carcinomatous meningitis.... [+6]

Read more
Status: Recruiting

A Study of ATG-022 in Patients With Advanced/Metastatic Solid Tumors

This is an Open, Multi-center, Phase I Clinical Study of ATG 022 in Patients with Advanced/metastatic Solid Tumors

Participants needed: 156
Trial details
Phase: Phase 1Age: 18+Biological sex: AllType: InterventionalSponsor: Antengene Biologics LimitedUpdated: Apr 15, 2026Locations: 22
Eligibility criteria

Provision of signed and dated, written informed consent prior to any study-speci... [+10]

Primary central nervous system disease or central nervous system metastatic dise... [+11]

Read more
Status: Recruiting

A Study of ATG-031 in Advanced Solid Tumors or B-cell Non-Hodgkin Lymphomas

ATG-031 study (alias: PERFORM) is a multicenter, open-label, Phase 1 study of ATG-031 in patients with advanced solid tumors or B-NHL. The study design includes a Dose Escalation Phase and a Dose Expansion Phase, and will enroll patients with advanced solid tumors (i.e., preferred tumor types) or relapsed/refractory (R/R) B-NHLs. The study's primary objective is to evaluate the safety and tolerability of ATG-031 and determine the RP2D（Refered Phase II dose） of ATG-031.

Participants needed: 80
Trial details
Phase: Phase 1Age: 18+Biological sex: AllType: InterventionalSponsor: Antengene Biologics LimitedUpdated: Jun 9, 2025Locations: 4
Eligibility criteria

Histological or cytologically confirmed advanced solid tumor or B-NHL which have... [+8]

Patients with CNS malignancies, except those who are clinically stable for ≥ 4 w... [+9]

Read more